Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs

Leeds & North Yorkshire
18 September 2014 17:10



London
18 September 2014 16:24



Sussex, Surrey
18 September 2014 16:06


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
markd@zenopa.com
+441494 818 049

Testimonials
Zenopa helps their candidates in a very professional way in order to further develop their careers. With Zenopa helping me in every step of the recruitment process and in providing guidance in answeri...
William, 2012

Gene target discovery 'could aid bowel cancer survival rates'

9 November 2010 00:00 in Medical Government/ NHS related news


New research has discovered a single gene target that could play a key role in improving survival rates among advanced bowel cancer sufferers.

A Cancer Research Wales and Tenovus-funded study conducted at Cardiff University has isolated a genetic region that is able to boost the activity of the nearby EIF3H gene, which is often associated with poor cancer survival.

According to findings presented at the National Cancer Research Institute (NCRI) Cancer Conference this week, bowel cancer sufferers with faults in this region survive for three months less on average than those without.

It is now thought that developing drugs to block the gene could help to prolong survival among patients in the future.

Chris Smith, one of the researchers involved in the study, said: "This is the first genetic region identified through genome-wide association studies shown to influence both survival and response to treatment in patients with advanced bowel cancer."

According to Cancer Research UK statistics, bowel cancer is the third most common variant of the condition in the country.ADNFCR-8000103-ID-800225468-ADNFCR

Other news stories from 09/11/2010

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd